Evidence map›Paper›PMID 42521807›Full record

ReviewNature protocols2026

Core2Edge: a human glioblastoma organoid-brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion.

Ahmad Melhem, Barbara E F Pregler, Juan Eduardo Rodriguez-Gatica, Lea L Friker, Jake Thomas, Marieta I Toma, Mike-Andrew Westhoff, Vidhya M Ravi, Valeri Borger, Dieter Henrik Heiland and 11 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ahmad Melhem *Department of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
Barbara E F Pregler *Department of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
Juan Eduardo Rodriguez-GaticaFunctional Neuroconnectomics Group, Institute for Experimental Epileptology and Cognition Research, University of Bonn, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-4123-0104
Lea L FrikerBrain Tumor Translational Research Group, University of Bonn, University Hospital Bonn, Bonn, Germany.
Jake ThomasBiology of Inflammation, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany.
Marieta I TomaDepartment of Pathology, University Hospital Bonn, Bonn, Germany.
Mike-Andrew WesthoffGerman Center for Child and Adolescent Health (DZKJ), partner site Ulm, Ulm, Germany.
Vidhya M RaviDepartment of Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0062-2099
Valeri BorgerDepartment of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
Dieter Henrik HeilandDepartment of Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-9258-3033
Julian P LayerBrain Tumor Translational Research Group, University of Bonn, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-7692-7775
Andreas SchlitzerBiology of Inflammation, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-7662-3712
Torsten PietschInstitute of Neuropathology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Michael HölzelInstitute of Experimental Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Andreas WahaInstitute of Neuropathology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Hartmut VatterDepartment of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
Martin K SchwarzFunctional Neuroconnectomics Group, Institute for Experimental Epileptology and Cognition Research, University of Bonn, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-5898-751X
Ulrich HerrlingerBrain Tumor Translational Research Group, University of Bonn, University Hospital Bonn, Bonn, Germany.
Ulrich KubitscheckClausius Institute of Physical and Theoretical Chemistry, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-3750-5355
Anna-Laura PotthoffDepartment of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany.
Matthias SchneiderDepartment of Neurosurgery, University of Bonn, University Hospital Bonn, Bonn, Germany. matthias.schneider@ukbonn.de.ORCID http://orcid.org/0000-0002-6025-7479

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 459047646
6 · The paper itself

Abstract

Glioblastomas function as intricate cellular networks that extend into the surrounding brain tissue, facilitating long-distance communication. This malignant connectivity spans from the tumor core to remote infiltration zones, in support of the concept of glioblastoma as a whole-brain disease. With growing ethical concerns in biomedical research and the inherent limitations of animal models in recapitulating human glioblastoma biology, there is an increasing demand for human ex vivo platforms capable of capturing the full infiltration spectrum from the tumor core to single-cell dispersion. Here we present a 3D, fully human ex vivo glioblastoma model (Core2Edge) that replicates this extensive infiltration range while preserving the intratumoral heterogeneity of the original tumor. This model involves implanting fluorescently labeled human glioblastoma organoids (GBOs) into organotypic human brain slices, maintaining the genetic integrity and cytoarchitecture of both brain and tumor. By combining tissue expansion with light-sheet fluorescence microscopy, we achieve high-resolution, 3D imaging of the entire GBO-brain slice model. This approach allows the study of initial infiltration steps, in-depth analysis of the invasive front, and exploration of cell-cell interactions between tumor cells and the tumor microenvironment, and offers a platform for drug screening and testing, reducing the need for animal models. Once GBOs are prepared, the protocol takes ~7-12 d. Key steps include brain slice preparation (~4-6 h, depending on quantity), 1 d for initial culture before GBO staining and transplantation, a variable culture period (≤10 d), and fixation (~8 h). The protocol requires experience with human brain slice and organoid culture.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.